Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
Holding XGN?
Track your performance easily
XGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $2.95
Previous Close$1.93
Volume21.57K
Average Volume (3M)35.44K
Market Cap
$33.53M
Enterprise Value$29.30M
Total Cash (Recent Filing)$27.27M
Total Debt (Recent Filing)$23.04M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 31, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding17,373,482
10 Day Avg. Volume22,462
30 Day Avg. Volume35,437
Standard Deviation0.18
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.70
Price to Sales (P/S)2.47
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda-1.97
Forecast
1Y Price Target
$6.00Price Target Upside203.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Exagen News
PremiumCompany Announcements
Exagen Inc. Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is XGN a Buy, Before Earnings?
PremiumPre-Earnings
Is XGN a Buy, Before Earnings?
PremiumCompany Announcements
Exagen Announces New CFO and Interim Leadership ChangesBulls Say, Bears Say
Bulls Say
Financial PerformanceXGN exhibits strong financial health with a significant increase in average selling prices, leading to a robust top and bottom line beat.
Future Growth ProspectsExagen's potential inclusion in the American College of Rheumatology guidelines could be a transformative event, increasing insurance coverage for AVISE Lupus and further propelling revenue growth.
Strategic InitiativesThe new CEO's strategic changes, including enhanced billing and collections processes, are positively impacting Exagen's financial performance.
Bears Say
Financial PerformanceXGN anticipates a decline in test volumes due to seasonal patterns, potentially impacting revenue.
Future ProjectionsXGN's projection of hitting a volume low might signal underlying challenges that could hamper growth expectations.
Insurance CoverageIncreased denial of XGN's tests by commercial payors, due to unrecognized new PLA codes, could affect financial stability.
---
Ownership Overview
56.23% Insiders
7.96% Mutual Funds
2.77% Other Institutional Investors
33.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XGN FAQ
What was Exagen Inc’s price range in the past 12 months?
Exagen Inc lowest stock price was $1.30 and its highest was $2.95 in the past 12 months.
What is Exagen Inc’s market cap?
Currently, no data Available
When is Exagen Inc’s upcoming earnings report date?
Exagen Inc’s upcoming earnings report date is Jul 31, 2024 which is 119 days ago.
How were Exagen Inc’s earnings last quarter?
Exagen Inc released its earnings results on May 13, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.361 by $0.171.
Is Exagen Inc overvalued?
According to Wall Street analysts Exagen Inc’s price is currently Undervalued.
Does Exagen Inc pay dividends?
Exagen Inc does not currently pay dividends.
What is Exagen Inc’s EPS estimate?
Exagen Inc’s EPS estimate is -$0.34.
How many shares outstanding does Exagen Inc have?
Exagen Inc has 17,373,482 shares outstanding.
What happened to Exagen Inc’s price movement after its last earnings report?
Exagen Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.361. Following the earnings report the stock price went up 4.459%.
Which hedge fund is a major shareholder of Exagen Inc?
Among the largest hedge funds holding Exagen Inc’s share is Platinum Investment Management. It holds Exagen Inc’s shares valued at N/A.
---
Exagen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (203.03% Upside)
$6.00 (203.03% Upside)
Hedge Fund Trend
Decreased
By 264.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $77.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.56%
12-Months-Change
Fundamentals
Return on Equity
-69.24%
Trailing 12-Months
Asset Growth
-35.88%
Trailing 12-Months
Company Description
Exagen Inc
Exagen Diagnostics Inc was incorporated under the laws of the state of New Mexico in 2002. The Company is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
---
XGN Earnings Call
Q1 2024
0:00 / 0:00
---
XGN Stock 12 Month Forecast
Average Price Target
$6.00
▲(203.03% Upside)
Technical Analysis
Best Analysts Covering XGN
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-18.31%
reiterated a buy rating 7 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -18.31% per trade.
---